No profile data available.
Amylyx Pharmaceuticals, Inc. (AMLX) is a healthcare company in the additional hormone and metabolic drugs industry, based in Cambridge, United States, with about 136 full-time employees.
It reported revenue of $0 for fiscal year 2025, down 100.0% from fiscal year 2024, and net income of -$144.74 million. Its market capitalization was $3.53 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States.
Amylyx Pharmaceuticals reported $0 in revenue for fiscal year 2025, down 100.0% from $87.37 million in fiscal year 2024.
$3.53 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (additional hormone and metabolic drugs) include Alnylam Pharmaceuticals, Inc. (ALNY), Corcept Therapeutics Incorporated (CORT), BridgeBio Pharma, Inc. (BBIO), MBX Biosciences, Inc. (MBX).